France’s Drug Reimbursement System
Executive Summary
France’s current drug evaluation system involves two scales: one to determine absolute medical benefit (whether a drug or procedure will be reimbursed or not) and another additional medical benefit (which determines the rate of reimbursement.)
You may also be interested in...
France Seeks Stronger Cost-Effectiveness Tools To Lower Drug Prices, But Pan-European Bulk Buying May Come First
France’s drugs assessment agency wants simpler, stronger rules to evaluate the cost-effectiveness of new drugs. But changes to the country’s complex reimbursement system may be too slow to address immediate budget concerns, making pan-European bulk buying appear a more likely near-term solution.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.